Health Catalyst (NASDAQ:HCAT) Price Target Raised to $9.00 at Royal Bank of Canada

Health Catalyst (NASDAQ:HCAT) had its price target boosted by Royal Bank of Canada from $8.00 to $9.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a sector perform rating on the stock.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Evercore ISI increased their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Piper Sandler reduced their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Finally, Stephens reduced their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Health Catalyst has an average rating of “Moderate Buy” and an average price target of $11.64.

Health Catalyst Price Performance

Shares of Health Catalyst stock traded down $0.62 during trading on Thursday, reaching $8.24. 674,641 shares of the company traded hands, compared to its average volume of 563,279. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a 50 day moving average price of $8.01 and a 200-day moving average price of $7.11. The firm has a market capitalization of $498.27 million, a PE ratio of -5.91 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. The firm had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The business’s revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.21) earnings per share. Equities research analysts expect that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,396 shares of company stock valued at $266,280 over the last three months. 2.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC purchased a new position in shares of Health Catalyst during the third quarter worth approximately $34,000. Nisa Investment Advisors LLC raised its position in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP raised its position in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the period. nVerses Capital LLC purchased a new position in Health Catalyst in the 3rd quarter worth $59,000. Finally, Perfromance Wealth Partners LLC purchased a new position in Health Catalyst in the 2nd quarter worth $64,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.